{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import json\n",
    "\n",
    "query = {}\n",
    "\n",
    "# queries must be formatted in Lucene ElasticSearch style\n",
    "# https://www.elastic.co/guide/en/elasticsearch/reference/current/full-text-queries.html\n",
    "\n",
    "# here are different query types :\n",
    "\n",
    "# MULTI_MATCH queries\n",
    "# use it for searching in specific fields, with a general OR or AND\n",
    "\n",
    "search_fields = [\"title\",\"abstract\",\"keywords\",\"mesh_terms\"]\n",
    "# you can use \"title^3\" for boosting by 3 scores in title\n",
    "keywords = \"BRCA2 cancer\"\n",
    "my_operator = \"and\" # default is \"or\"\n",
    "my_type = \"phrase\" # use it for phrase matching (exact expression)\n",
    "\n",
    "my_query = {\n",
    "    \"size\": 10, # maximum amount of hits returned\n",
    "    \"from\" : 0, # offset from the first result you want to fetch\n",
    "    \"query\": {\n",
    "        \"multi_match\" : {\n",
    "            \"query\" : keywords,\n",
    "            \"fields\" : search_fields\n",
    "            #,\"operator\" : my_operator\n",
    "            #,\"type\" = \"phrase\"\n",
    "            }\n",
    "        }\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ex: (\"EML4\" OR \"ALK\" in title) AND (\"Lung Cancer\" in journal)\n",
    "my_query = {\n",
    "    \"query\": {\n",
    "        \"bool\" : {\n",
    "            \"must\" :[ # AND\n",
    "                {\n",
    "                    \"bool\" : {\n",
    "                        \"should\" :[ # OR\n",
    "                            {\n",
    "                                \"match\" : {\"title\": \"EML4\"},\n",
    "                                \"match\" : {\"title\": \"ALK\"}\n",
    "                                }\n",
    "                            ]\n",
    "                        }\n",
    "                    },\n",
    "                {\n",
    "                    \"match\" : {\"journal\": \"Lung Cancer\"}\n",
    "                    }\n",
    "                ]\n",
    "            }\n",
    "        }\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"32576444\",\n",
      "    \"_score\": 24.198877,\n",
      "    \"_source\": {\n",
      "      \"title\": \"Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.\",\n",
      "      \"abstract\": \"\",\n",
      "      \"journal\": \"Clinical lung cancer\",\n",
      "      \"authors\": \"Chen X|Zhao G|Zhong P|Zhang M|Chen R|Zhang D\",\n",
      "      \"affiliations\": \"Department of Thoracic Surgery, Fujian Province Cancer Hospital, Fuzhou, Fujian, China.|Department of Thoracic Surgery, Fujian Province Cancer Hospital, Fuzhou, Fujian, China.|Department of Gynecological Oncology Radiotherapy, Fujian Province Cancer Hospital, Fuzhou, Fujian, China.|Department of Medical Center, Geneplus-Beijing Ltd., Beijing, China.|Department of Medical Center, Geneplus-Beijing Ltd., Beijing, China.|Department of Thoracic Surgery, Fujian Province Cancer Hospital, Fuzhou, Fujian, China. Electronic address: surgzhangderong@163.com.\",\n",
      "      \"pubyear\": 2020,\n",
      "      \"entrez_date\": \"2020-06-25\",\n",
      "      \"pmid\": \"32576444\",\n",
      "      \"mesh_terms\": \"\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"\",\n",
      "      \"publication_types\": \"Case Reports\",\n",
      "      \"keywords\": \"Chr2 30297612-ALK|Crizotinib|Exon 18|Intergenic fusion|Next-generation sequencing\",\n",
      "      \"pmcid\": \"\",\n",
      "      \"doi\": \"10.1016/j.cllc.2020.04.014\",\n",
      "      \"medline_ta\": \"Clin Lung Cancer\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene BRM_ARATH|Gene NX_Q9UM73|Gene NX_Q9UM73|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene BRM_ARATH|Gene NX_Q9UM73|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|MESH D059014\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"27130468\",\n",
      "    \"_score\": 23.877148,\n",
      "    \"_source\": {\n",
      "      \"title\": \"Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.\",\n",
      "      \"abstract\": \"BACKGROUND\\nSecondary anaplastic lymphoma kinase (ALK) mutation may occur in patients with advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors, but its nature is not well-known.\\n\\n\\nPATIENTS AND METHODS\\nWe analyzed tumor specimens after the failure of treatment with ALK inhibitor(s) (crizotinib, alectinib, and ceritinib) for secondary ALK kinase domain mutation, EGFR, K-ras, and PIK3CA mutations. The literature regarding acquired ALK-inhibitor(s) resistance was also reviewed.\\n\\n\\nRESULTS\\nAmong 59 patients who received ALK inhibitor(s) during the period of December 2010 to April 2015, 7 had re-biopsied tumor specimens for analyses following ALK inhibitor(s) failure. One had G1202R after crizotinib and alectinib failure, and 6 were wild type. No EGFR, K-ras, or PIK3CA mutations were found. In our review of the literature and taken together with our patients, 25 of the 88 (28%) patients with crizotinib failure had secondary ALK mutation; L1196M mutation was most common (n\\u00a0= 11). Patients with secondary ALK mutation other than L1196M had a longer progression-free survival after crizotinib than patients with L1196M (median, 12.0 vs. 7.0 months; P\\u00a0= .04). Of the 9 patients with alectinib failure, 5 had I1171 mutation and 2 had G1202R. Of the 11 patients with ceritinib failure, 2 had G1202R, 1 had F1174C, and 1 had both G1202R and F1174V. I1171 mutation, G1202R, and F1174 mutations were also found in crizotinib-failed patients.\\n\\n\\nCONCLUSIONS\\nSome acquired ALK mutations may cause co-resistance to other ALK inhibitors. Re-biopsy for ALK mutation analysis might be suggested prior to choosing a second-line ALK inhibitor treatment.\",\n",
      "      \"journal\": \"Clinical lung cancer\",\n",
      "      \"authors\": \"Lin YT|Yu CJ|Yang JC|Shih JY\",\n",
      "      \"affiliations\": \"Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan.|Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.|Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology and Cancer Research Centre, College of Medicine, National Taiwan University, Taipei, Taiwan.|Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: jyshih@ntu.edu.tw.\",\n",
      "      \"pubyear\": 2016,\n",
      "      \"entrez_date\": \"2016-05-01\",\n",
      "      \"pmid\": \"27130468\",\n",
      "      \"mesh_terms\": \"D000077548:Anaplastic Lymphoma Kinase|D002227:Carbazoles|D002289:Carcinoma, Non-Small-Cell Lung|D000077547:Crizotinib|D018572:Disease-Free Survival|D019008:Drug Resistance, Neoplasm|D006801:Humans|D008175:Lung Neoplasms|D009154:Mutation|D010880:Piperidines|D047428:Protein Kinase Inhibitors|D011720:Pyrazoles|D011725:Pyridines|D011743:Pyrimidines|D020794:Receptor Protein-Tyrosine Kinases|D013450:Sulfones|D017211:Treatment Failure\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"RN 0, D002227:Carbazoles|RN 0, D010880:Piperidines|RN 0, D047428:Protein Kinase Inhibitors|RN 0, D011720:Pyrazoles|RN 0, D011725:Pyridines|RN 0, D011743:Pyrimidines|RN 0, D013450:Sulfones|RN 53AH36668S, D000077547:Crizotinib|RN EC 2.7.10.1, C000626173:ALK protein, human|RN EC 2.7.10.1, D000077548:Anaplastic Lymphoma Kinase|RN EC 2.7.10.1, D020794:Receptor Protein-Tyrosine Kinases|RN K418KG2GET, C586847:ceritinib|RN LIJ4CT1Z3Y, C582670:alectinib\",\n",
      "      \"publication_types\": \"Journal Article|Review\",\n",
      "      \"keywords\": \"ALK inhibitor resistance|Acquired resistance|Alectinib|Ceritinib|Crizotinib\",\n",
      "      \"pmcid\": \"\",\n",
      "      \"doi\": \"10.1016/j.cllc.2016.03.005\",\n",
      "      \"medline_ta\": \"Clin Lung Cancer\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Disease C3208|Disease C5165|Disease C7587|MESH D008223|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C6916|Disease C4878|Disease C7377|MESH D008175|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Disease C6916|Disease C4878|Disease C7377|MESH D008175|Chemical CHEBI:62434|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Disease C2926|MESH D002289|Gene NX_Q9UM73|Gene NX_Q9UM73|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Drug L01XE36|Chemical CHEBI:90936|Drug DB11363|Drug L01XE28|Chemical CHEBI:78432|Drug DB09063|Molecular Function GO:0005006|Gene NX_P00533|Gene EGFR_CHICK|Gene EGFR_DROME|Gene EGFR_HUMAN|Gene EGFR_MACMU|Gene EGFR_MOUSE|Gene NX_P01116|Gene RASK_CYPCA|Gene RASK_HUMAN|Gene RASK_MOUSE|Gene RASK_ORYLA|Gene RASK_RAT|Gene RASK_XENLA|Drug DB01367|Drug DB14954|Gene NX_P42336|Gene PK3CA_BOVIN|Gene PK3CA_HUMAN|Gene PK3CA_MOUSE|Gene PK3CA_RAT|MESH D000077548|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_O75888|Gene NX_Q92688|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Drug L01XE36|Chemical CHEBI:90936|Drug DB11363|Molecular Function GO:0005006|Gene NX_P00533|Gene EGFR_CHICK|Gene EGFR_DROME|Gene EGFR_HUMAN|Gene EGFR_MACMU|Gene EGFR_MOUSE|Gene NX_P01116|Gene RASK_CYPCA|Gene RASK_HUMAN|Gene RASK_MOUSE|Gene RASK_ORYLA|Gene RASK_RAT|Gene RASK_XENLA|Drug DB01367|Drug DB14954|Gene NX_P42336|Gene PK3CA_BOVIN|Gene PK3CA_HUMAN|Gene PK3CA_MOUSE|Gene PK3CA_RAT|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Gene NX_Q9UM73|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|MESH D000077982|Drug L01XE36|Chemical CHEBI:90936|Drug DB11363|Drug L01XE28|Chemical CHEBI:78432|Drug DB09063|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|MESH D001706|Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type1 MFUN_04.001|Chemical CHEBI:62434|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Disease C6916|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:48513|MESH D002227|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|MESH D018572|Disease C3262|Disease C6283|MESH D009369|Biological Process GO:0009315|Biological Process GO:0042493|MESH D004351|MESH D009369|Disease C3200|MESH D008175|Chemical CHEBI:26151|MESH D010880|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Chemical CHEBI:26410|MESH D011720|Chemical CHEBI:26421|MESH D011725|Chemical CHEBI:39447|MESH D011743|Chemical CHEBI:17895|Chemical CHEBI:18186|Drug DB00135|MESH D014443|MESH D010770|MESH D011505|MESH D020794|Chemical CHEBI:35850|MESH D013450|MESH D017211|Chemical CHEBI:48513|MESH D002227|Chemical CHEBI:26151|MESH D010880|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Chemical CHEBI:26410|MESH D011720|Chemical CHEBI:26421|MESH D011725|Chemical CHEBI:39447|MESH D011743|Chemical CHEBI:35850|MESH D013450|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Species 9606|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:17895|Chemical CHEBI:18186|Drug DB00135|MESH D014443|MESH D010770|MESH D011505|MESH D020794|Drug L01XE28|Chemical CHEBI:78432|Drug DB09063|Drug L01XE36|Chemical CHEBI:90936|Drug DB11363|Gene NX_Q9UM73|DisProt_type1 MFUN_04.001|Chemical CHEBI:62434|Drug L01XE36|Chemical CHEBI:90936|Drug DB11363|Drug L01XE28|Chemical CHEBI:78432|Drug DB09063|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"31147208\",\n",
      "    \"_score\": 23.465513,\n",
      "    \"_source\": {\n",
      "      \"title\": \"Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.\",\n",
      "      \"abstract\": \"BACKGROUND\\nAnaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have shown efficacy in the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), but the disease eventually progresses in all patients. In many cases, resistance to ALK TKIs arises through ALK mutations. Although clinical and biological data suggest variations in TKI efficacy according to the mechanism of resistance, ALK mutations are still rarely investigated in routine practice.\\n\\n\\nMATERIALS AND METHODS\\nWe performed a retrospective multicentric study with an aim to determine the frequency and clinical relevance of ALK alterations detected using targeted next-generation sequencing in patients with advanced ALK-rearranged NSCLC after progression during an ALK TKI treatment. Data on clinical, pathological, and molecular characteristics and patient outcomes were collected.\\n\\n\\nRESULTS\\nWe identified 23 patients with advanced ALK-rearranged NSCLC who, between January 2012 and May 2017, had undergone at least 1 repeat biopsy at progression during an ALK TKI treatment. A resistance mechanism was identified in 9 of the 23 patients (39%). The anomalies involved included 9 ALK mutations in 8 patients and one ALK amplification. The ALK mutation rate was 15% after failure of a first ALK TKI and 33% after failure of 2 ALK TKI treatments. Five of 7 patients who received a different ALK TKI after detection of an ALK mutation achieved an objective response. All of the patients who received a TKI presumed to act on the detected ALK mutant achieved disease control.\\n\\n\\nCONCLUSION\\nTargeted next-generation sequencing is suitable for detecting ALK resistance mutations in ALK-rearranged NSCLC patients in routine practice. It might help select the best treatment at the time of disease progression during treatment with an ALK TKI.\",\n",
      "      \"journal\": \"Clinical lung cancer\",\n",
      "      \"authors\": \"Jamme P|Descarpentries C|Gervais R|Dansin E|Wislez M|Gr\\u00e9goire V|Richard N|Baldacci S|Rabbe N|Kyheng M|Kherrouche Z|Escande F|Copin MC|Cortot AB\",\n",
      "      \"affiliations\": \"Thoracic Oncology Department, Univ. Lille CHU Lille, Lille, France; UMR 8161 M3T Mechanisms of Tumorigenesis and Targeted Therapies, Univ. Lille CNRS Institut Pasteur de Lille, Lille, France.|Oncology and Molecular Genetics-Laboratory Division of Biochemistry and Molecular Biology, CHU Lille Univ. Lille, Lille, France.|Thoracic Oncology Department, Centre Fran\\u00e7ois Baclesse, Caen, France.|Head and Neck and Thoracic Cancers Department, Centre Oscar Lambret, Lille, France.|Service de Pneumologie, AP-HP H\\u00f4pital Tenon Sorbonne Universit\\u00e9s- UPMC Univ Paris 06 -GRC n\\u00b004 Theranoscan, Paris, France.|Institut de Pathologie, Univ. Lille CHU Lille, Lille, France.|Department of Genetics-Molecular Genetics Laboratory UNICAEN EA7450 BioTARGen, Caen Normandy University CHU de Caen, Caen, France.|Thoracic Oncology Department, Univ. Lille CHU Lille, Lille, France.|Service de Pneumologie, AP-HP H\\u00f4pital Tenon Sorbonne Universit\\u00e9s- UPMC Univ Paris 06 -GRC n\\u00b004 Theranoscan, Paris, France.|EA 2694 Sant\\u00e9 publique: \\u00e9pid\\u00e9miologie et qualit\\u00e9 des soins, Univ. Lille CHU Lille, Lille, France.|UMR 8161 M3T Mechanisms of Tumorigenesis and Targeted Therapies, Univ. Lille CNRS Institut Pasteur de Lille, Lille, France.|Oncology and Molecular Genetics-Laboratory Division of Biochemistry and Molecular Biology, CHU Lille Univ. Lille, Lille, France.|UMR 8161 M3T Mechanisms of Tumorigenesis and Targeted Therapies, Univ. Lille CNRS Institut Pasteur de Lille, Lille, France; Institut de Pathologie, Univ. Lille CHU Lille, Lille, France.|Thoracic Oncology Department, Univ. Lille CHU Lille, Lille, France; UMR 8161 M3T Mechanisms of Tumorigenesis and Targeted Therapies, Univ. Lille CNRS Institut Pasteur de Lille, Lille, France. Electronic address: alexis.cortot@chru-lille.fr.\",\n",
      "      \"pubyear\": 2019,\n",
      "      \"entrez_date\": \"2019-06-01\",\n",
      "      \"pmid\": \"31147208\",\n",
      "      \"mesh_terms\": \"D000293:Adolescent|D000328:Adult|D000368:Aged|D000077548:Anaplastic Lymphoma Kinase|D000971:Antineoplastic Combined Chemotherapy Protocols|D002289:Carcinoma, Non-Small-Cell Lung|D000077547:Crizotinib|D019008:Drug Resistance, Neoplasm|D005260:Female|D015321:Gene Rearrangement|D006801:Humans|D008175:Lung Neoplasms|D008297:Male|D008875:Middle Aged|D009367:Neoplasm Staging|D047428:Protein Kinase Inhibitors|D012189:Retrospective Studies|D055815:Young Adult\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"RN 0, D047428:Protein Kinase Inhibitors|RN 53AH36668S, D000077547:Crizotinib|RN EC 2.7.10.1, C000626173:ALK protein, human|RN EC 2.7.10.1, D000077548:Anaplastic Lymphoma Kinase\",\n",
      "      \"publication_types\": \"Journal Article|Multicenter Study|Observational Study\",\n",
      "      \"keywords\": \"Anaplastic lymphoma kinase|Lung neoplasm|Mutation|Real-world evidence|Resistance\",\n",
      "      \"pmcid\": \"\",\n",
      "      \"doi\": \"10.1016/j.cllc.2019.02.013\",\n",
      "      \"medline_ta\": \"Clin Lung Cancer\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Disease C2926|Chemical CHEBI:62434|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Gene NX_Q9UM73|Gene NX_Q9UM73|Chemical CHEBI:17895|Chemical CHEBI:18186|Drug DB00135|MESH D014443|DisProt_type2 MFUN_04.001|Disease C2926|Disease C6916|MESH D011505|Disease C4878|Disease C7377|MESH D008175|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:38637|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C2926|MESH D059014|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C2926|MESH D001706|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C45581|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|MESH D059645|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_P01011|Gene NX_Q5TD97|Gene NX_Q9UM73|Disease C54033|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C2926|MESH D059014|Gene NX_Q9UM73|Disease C143201|Disease C17747|Disease C19987|Disease C35571|MESH D018450|MESH D000293|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Disease C6916|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:35610|MESH D000971|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C3262|Disease C6283|MESH D009369|Biological Process GO:0009315|Biological Process GO:0042493|MESH D004351|Disease C133155|MESH D015321|MESH D009369|Disease C3200|MESH D008175|Disease C159238|MESH D008875|Disease C3262|Disease C6283|MESH D009369|MESH D009367|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|MESH D012189|MESH D055815|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Species 9606|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|MESH D009369|MESH D008175\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"24984564\",\n",
      "    \"_score\": 23.465513,\n",
      "    \"_source\": {\n",
      "      \"title\": \"ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?\",\n",
      "      \"abstract\": \"Genetic insight into the pathogenesis of lung cancer has paved the way for a new era in its treatment. Recently, anaplastic lymphoma kinase (ALK) has been identified as exerting a potent transforming effect through genetic rearrangement in patients with lung cancer. Preclinical and single-arm phase I studies have shown that patients with ALK-rearranged non-small cell lung cancer (NSCLC) can be successfully treated with crizotinib. Furthermore, a phase III randomized study indicated that crizotinib is superior to standard chemotherapy in the treatment of patients with NSCLC harboring the ALK rearrangement who had received 1 previous platinum-based chemotherapy. Despite the excellent efficacy of crizotinib in patients with ALK-positive (ALK(+)) lung cancer, resistance mechanisms--such as secondary mutations in the ALK gene, the activation of other oncogenes, and so on--have been identified as conferring resistance to crizotinib. Second-generation ALK inhibitors, such as alectinib and ceritinib, have been shown to be effective not only in crizotinib-naive patients but also in those resistant to crizotinib. Therefore, although some agents specifically targeting ALK have been developed and their efficacy has been documented, how ALK inhibitors should be administered in the setting of ALK-rearranged NSCLC remains to be fully elucidated. Can second-generation ALK inhibitors replace crizotinib? Is crizotinib just a first-generation ALK inhibitor? Is the sequential use of crizotinib and second-generation ALK inhibitors the best method? In this article, we review the preclinical and clinical results regarding crizotinib and second-generation ALK inhibitors, as well as the resistance mechanisms, and discuss the best methods for treating patients with ALK(+) NSCLC.\",\n",
      "      \"journal\": \"Clinical lung cancer\",\n",
      "      \"authors\": \"Toyokawa G|Seto T\",\n",
      "      \"affiliations\": \"Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.|Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan. Electronic address: tseto@nk-cc.go.jp.\",\n",
      "      \"pubyear\": 2014,\n",
      "      \"entrez_date\": \"2014-07-03\",\n",
      "      \"pmid\": \"24984564\",\n",
      "      \"mesh_terms\": \"D000077548:Anaplastic Lymphoma Kinase|D000818:Animals|D000970:Antineoplastic Agents|D002289:Carcinoma, Non-Small-Cell Lung|D000077547:Crizotinib|D019008:Drug Resistance, Neoplasm|D006801:Humans|D008175:Lung Neoplasms|D009154:Mutation|D047428:Protein Kinase Inhibitors|D011720:Pyrazoles|D011725:Pyridines|D020794:Receptor Protein-Tyrosine Kinases\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"RN 0, D000970:Antineoplastic Agents|RN 0, D047428:Protein Kinase Inhibitors|RN 0, D011720:Pyrazoles|RN 0, D011725:Pyridines|RN 53AH36668S, D000077547:Crizotinib|RN EC 2.7.10.1, C000626173:ALK protein, human|RN EC 2.7.10.1, D000077548:Anaplastic Lymphoma Kinase|RN EC 2.7.10.1, D020794:Receptor Protein-Tyrosine Kinases\",\n",
      "      \"publication_types\": \"Journal Article|Research Support, Non-U.S. Gov't|Review\",\n",
      "      \"keywords\": \"ALK inhibitors|Anaplastic lymphoma kinase|Crizotinib|Non\\u2013small-cell lung cancer|Resistance mechanisms\",\n",
      "      \"pmcid\": \"\",\n",
      "      \"doi\": \"10.1016/j.cllc.2014.05.001\",\n",
      "      \"medline_ta\": \"Clin Lung Cancer\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|Disease C18264|Biological Process GO:0009405|Disease C119024|Disease C4878|Disease C7377|MESH D008175|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Gene NX_Q9UM73|Disease C17212|Disease C6916|Disease C4878|Disease C7377|MESH D008175|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Gene NX_Q9UM73|Disease C2926|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C4878|Disease C7377|MESH D008175|Disease C2926|MESH D002289|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C2926|Gene NX_Q9UM73|Drug DB12257|Disease C129574|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|MESH D009857|Disease C4878|Disease C7377|MESH D008175|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Drug L01XE36|Chemical CHEBI:90936|Drug DB11363|Drug L01XE28|Chemical CHEBI:78432|Drug DB09063|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Chemical CHEBI:62434|DisProt_type2 MFUN_02.002|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Disease C2926|Chemical CHEBI:62434|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Chemical CHEBI:62434|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|DisProt_type1 MFUN_04.001|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Disease C2926|Chemical CHEBI:62434|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Disease C6916|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:35610|Drug L01|Chemical CHEBI:35610|MESH D000970|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C3262|Disease C6283|MESH D009369|Biological Process GO:0009315|Biological Process GO:0042493|MESH D004351|MESH D009369|Disease C3200|MESH D008175|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Chemical CHEBI:26410|MESH D011720|Chemical CHEBI:26421|MESH D011725|Chemical CHEBI:17895|Chemical CHEBI:18186|Drug DB00135|MESH D014443|MESH D010770|MESH D011505|MESH D020794|Chemical CHEBI:35610|Drug L01|Chemical CHEBI:35610|MESH D000970|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Chemical CHEBI:26410|MESH D011720|Chemical CHEBI:26421|MESH D011725|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Species 9606|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:17895|Chemical CHEBI:18186|Drug DB00135|MESH D014443|MESH D010770|MESH D011505|MESH D020794|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|MESH D008175\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"33277054\",\n",
      "    \"_score\": 23.340462,\n",
      "    \"_source\": {\n",
      "      \"title\": \"GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.\",\n",
      "      \"abstract\": \"\",\n",
      "      \"journal\": \"Lung cancer (Amsterdam, Netherlands)\",\n",
      "      \"authors\": \"Xiong L|Li X|Chen D|Li S|Luo L\",\n",
      "      \"affiliations\": \"Department of Cardiothoracic Surgery, The Affiliated Jinling Hospital of Nanjing Medical University, Nanjing, China.|Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.|The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.|The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.|Department of Cardiothoracic Surgery, School of Medicine, Nanjing University, Nanjing, China. Electronic address: luolgnjdx@126.com.\",\n",
      "      \"pubyear\": 2020,\n",
      "      \"entrez_date\": \"2020-12-05\",\n",
      "      \"pmid\": \"33277054\",\n",
      "      \"mesh_terms\": \"\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"\",\n",
      "      \"publication_types\": \"Letter\",\n",
      "      \"keywords\": \"\",\n",
      "      \"pmcid\": \"\",\n",
      "      \"doi\": \"10.1016/j.lungcan.2020.11.021\",\n",
      "      \"medline_ta\": \"Lung Cancer\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene NX_P35052|Gene GPC1_ARATH|Gene GPC1_BOVIN|Gene GPC1_CHICK|Gene GPC1_DANRE|Gene GPC1_HUMAN|Gene GPC1_MOUSE|Gene GPC1_RAT|Gene GBG_CAEEL|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C27004|Disease 8033/3\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"25806324\",\n",
      "    \"_score\": 23.074339,\n",
      "    \"_source\": {\n",
      "      \"title\": \"Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer.\",\n",
      "      \"abstract\": \"\",\n",
      "      \"journal\": \"Translational lung cancer research\",\n",
      "      \"authors\": \"Costa DB\",\n",
      "      \"affiliations\": \"Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.\",\n",
      "      \"pubyear\": 2014,\n",
      "      \"entrez_date\": \"2015-03-26\",\n",
      "      \"pmid\": \"25806324\",\n",
      "      \"mesh_terms\": \"\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"\",\n",
      "      \"publication_types\": \"Journal Article\",\n",
      "      \"keywords\": \"\",\n",
      "      \"pmcid\": \"PMC4367670\",\n",
      "      \"doi\": \"10.3978/j.issn.2218-6751.2014.08.01\",\n",
      "      \"medline_ta\": \"Transl Lung Cancer Res\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|Disease C4878|Disease C7377|MESH D008175\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"30642554\",\n",
      "    \"_score\": 22.819511,\n",
      "    \"_source\": {\n",
      "      \"title\": \"Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.\",\n",
      "      \"abstract\": \"Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) treated with ALK tyrosine kinase inhibitor (TKI) eventually acquires resistance to the treatment. However, our current knowledge regarding the resistance mechanisms is based on non-synonymous mutation and amplification in ALK, with the reasons still unknown for nearly half of all such cases. Other than genomic alteration as a resistance mechanism, up to 10% of NSCLC with activating epithelial growth factor receptor (EGFR) mutation showed resistance to EGFR TKI through histologic transformation. Although limited in number, there are cases showing transformed samples retaining the initial genomic alteration, which support lineage transition as a novel resistance mechanism. In this report, we described the first case of squamous cell carcinoma (SCC) transformation from adenocarcinoma (ADC) in NSCLC with ALK rearrangement after treatment with ALK TKI.\",\n",
      "      \"journal\": \"Lung cancer (Amsterdam, Netherlands)\",\n",
      "      \"authors\": \"Park S|Han J|Sun JM\",\n",
      "      \"affiliations\": \"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.|Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.|Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: jongmu.sun@skku.edu.\",\n",
      "      \"pubyear\": 2019,\n",
      "      \"entrez_date\": \"2019-01-16\",\n",
      "      \"pmid\": \"30642554\",\n",
      "      \"mesh_terms\": \"D000230:Adenocarcinoma|D000077548:Anaplastic Lymphoma Kinase|D000970:Antineoplastic Agents|D002294:Carcinoma, Squamous Cell|D054337:Cell Dedifferentiation|D019070:Cell Lineage|D002471:Cell Transformation, Neoplastic|D000077547:Crizotinib|D019008:Drug Resistance, Neoplasm|D005260:Female|D015321:Gene Rearrangement|D006801:Humans|D008175:Lung Neoplasms|D008875:Middle Aged|D047428:Protein Kinase Inhibitors\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"RN 0, D000970:Antineoplastic Agents|RN 0, D047428:Protein Kinase Inhibitors|RN 53AH36668S, D000077547:Crizotinib|RN EC 2.7.10.1, C000626173:ALK protein, human|RN EC 2.7.10.1, D000077548:Anaplastic Lymphoma Kinase\",\n",
      "      \"publication_types\": \"Journal Article\",\n",
      "      \"keywords\": \"Adenocarcinoma|Anaplastic lymphoma kinase|Non-small cell lung cancer|Squamous cell carcinoma\",\n",
      "      \"pmcid\": \"\",\n",
      "      \"doi\": \"10.1016/j.lungcan.2018.11.027\",\n",
      "      \"medline_ta\": \"Lung Cancer\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Disease C17212|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|DisProt_type1 MFUN_04.001|MESH D004847|MESH D000359|Chemical CHEBI:62434|Disease C2929|MESH D002294|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C2926|Chemical CHEBI:17895|Chemical CHEBI:18186|Drug DB00135|MESH D014443|DisProt_type1 MFUN_04.001|Disease C6916|Disease C4878|Disease C7377|MESH D008175|MESH D011505|Biological Process GO:0033673|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:38637|Disease C2926|MESH D002289|Disease C45581|Gene NX_Q9UM73|Disease C168276|Disease C168459|Disease C168460|Disease C168461|Disease C168462|Disease C168463|Disease C168464|Disease C168466|Disease C168467|Disease C168468|Disease C168469|Disease C168470|Disease C168471|Disease C168472|Disease C168473|Disease C168474|Disease C168475|Disease C168476|Disease C168477|Disease C168479|Disease C168480|Disease C168481|DisProt_type1 MFUN_10.001|Disease C18133|Disease C2926|Molecular Function GO:0005006|Gene NX_P00533|Gene EGFR_CHICK|Gene EGFR_DROME|Gene EGFR_HUMAN|Gene EGFR_MACMU|Gene EGFR_MOUSE|Molecular Function GO:0005006|Gene NX_P00533|Gene EGFR_CHICK|Gene EGFR_DROME|Gene EGFR_HUMAN|Gene EGFR_MACMU|Gene EGFR_MOUSE|Disease C17212|Disease C17212|Disease C18134|Disease C45590|Disease C17212|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Gene NX_Q96A70|Disease C2926|Gene NX_Q9UM73|Gene NX_Q9UM73|MESH D004847|Disease C129574|MESH D000359|Disease C2929|MESH D002294|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Disease C6916|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:35610|Drug L01|Chemical CHEBI:35610|MESH D000970|MESH D004847|Biological Process GO:0043696|Biological Process GO:0043697|MESH D054337|MESH D019070|Disease C17212|Disease C17212|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C3262|Disease C6283|MESH D009369|Biological Process GO:0009315|Biological Process GO:0042493|MESH D004351|Disease C133155|MESH D015321|MESH D009369|Disease C3200|MESH D008175|Disease C159238|MESH D008875|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Chemical CHEBI:35610|Drug L01|Chemical CHEBI:35610|MESH D000970|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Species 9606|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|MESH D000230|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|MESH D008175|MESH D002289|MESH D004847|MESH D002294\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"31521978\",\n",
      "    \"_score\": 22.819511,\n",
      "    \"_source\": {\n",
      "      \"title\": \"The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.\",\n",
      "      \"abstract\": \"OBJECTIVES\\nAnaplastic lymphoma kinase (ALK) has been proven to be another driver oncogene that accounts for 3%-7% of non-small-cell lung cancer, and it is more common in young patients and nonsmokers. ALK rearrangements have been previously identified in about 5.1% of lung adenocarcinoma, including EML4-ALK fusion variants, KIF5B-ALK and TFG-ALK. However, a TNIP2-ALK fusion has not been reported in lung adenocarcinoma. Herein, we described a rare case of ALK-rearranged lung adenocarcinoma responding to crizotinib.\\n\\n\\nMATERIALS AND METHODS\\nImmunohistochemistry (IHC) assay and comprehensive next-generation sequencing (NGS) were performed on the aspirated biopsied tumor tissue.\\n\\n\\nRESULTS\\nThe IHC analysis revealed an ALK-positive tumor, while NGS detected a TNIP2-ALK fusion. The patient achieved continuous remission after treatment with crizotinib (250\\u202fmg, twice a day).\\n\\n\\nCONCLUSION\\nThis case provides valuable information on the response to crizotinib of patients with TNIP2-ALK fusion and better understanding of ALK-TKI applications in the future. NGS is a new method that can offer effective detection of gene fusion and gene mutations.\",\n",
      "      \"journal\": \"Lung cancer (Amsterdam, Netherlands)\",\n",
      "      \"authors\": \"Feng T|Chen Z|Gu J|Wang Y|Zhang J|Min L\",\n",
      "      \"affiliations\": \"Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, The First Clinical College of Dalian Medical University, Yangzhou 225001, Jiangsu, China.|Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, The First Clinical College of Dalian Medical University, Yangzhou 225001, Jiangsu, China.|Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou 225001, Jiangsu, China.|Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, The First Clinical College of Dalian Medical University, Yangzhou 225001, Jiangsu, China.|Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou 225001, Jiangsu, China.|Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, The First Clinical College of Dalian Medical University, Yangzhou 225001, Jiangsu, China. Electronic address: minlingfeng@126.com.\",\n",
      "      \"pubyear\": 2019,\n",
      "      \"entrez_date\": \"2019-09-16\",\n",
      "      \"pmid\": \"31521978\",\n",
      "      \"mesh_terms\": \"D048868:Adaptor Proteins, Signal Transducing|D000077192:Adenocarcinoma of Lung|D000077548:Anaplastic Lymphoma Kinase|D000077547:Crizotinib|D005260:Female|D015321:Gene Rearrangement|D059014:High-Throughput Nucleotide Sequencing|D006801:Humans|D008175:Lung Neoplasms|D008875:Middle Aged|D009154:Mutation|D015514:Oncogene Proteins, Fusion|D011379:Prognosis|D047428:Protein Kinase Inhibitors\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"RN 0, D048868:Adaptor Proteins, Signal Transducing|RN 0, D015514:Oncogene Proteins, Fusion|RN 0, D047428:Protein Kinase Inhibitors|RN 0, C434062:TNIP2 protein, human|RN 53AH36668S, D000077547:Crizotinib|RN EC 2.7.10.1, C000626173:ALK protein, human|RN EC 2.7.10.1, D000077548:Anaplastic Lymphoma Kinase\",\n",
      "      \"publication_types\": \"Case Reports|Journal Article|Research Support, Non-U.S. Gov't\",\n",
      "      \"keywords\": \"ALKfusion|NGS|NSCLC|TNIP2|crizotinib\",\n",
      "      \"pmcid\": \"\",\n",
      "      \"doi\": \"10.1016/j.lungcan.2019.08.032\",\n",
      "      \"medline_ta\": \"Lung Cancer\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene NX_Q8NFZ5|Gene TNIP2_HUMAN|Gene TNIP2_MOUSE|Gene NX_Q9UM73|Gene NX_Q9UM73|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Disease C3512|MESH D000077192|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Gene NX_Q9UM73|MESH D000078405|Disease C6916|Disease C4878|Disease C7377|MESH D008175|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Gene NX_Q9HC35|Gene EMAL4_HUMAN|Gene EMAL4_MOUSE|Gene EMAL4_XENLA|Gene EML4_ARATH|Gene NX_P33176|Gene KINH_HUMAN|Gene KINH_MOUSE|Gene KINH_RAT|Gene NX_Q92734|Gene TFG_HUMAN|Disease C3512|MESH D000077192|Gene NX_Q8NFZ5|Gene TNIP2_HUMAN|Gene TNIP2_MOUSE|Gene NX_Q9UM73|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Disease C3512|MESH D000077192|Gene NX_Q9UM73|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C3512|MESH D000077192|DisProt_type3 PR021|MESH D007150|PPI-PTM PPI:19|MESH D059014|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q8NFZ5|Gene TNIP2_HUMAN|Gene TNIP2_MOUSE|Disease C18246|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|MESH D000359|Disease C54033|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q8NFZ5|Gene TNIP2_HUMAN|Gene TNIP2_MOUSE|Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C20195|Disease C45584|MESH D050939|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Disease C3512|MESH D000077192|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Disease C6916|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C133155|MESH D015321|Chemical CHEBI:36976|MESH D059014|MESH D009369|Disease C3200|MESH D008175|Disease C159238|MESH D008875|MESH D015513|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|MESH D015513|DisProt_type2 MFUN_04.001|MESH D011494|Drug L01XE|Chemical CHEBI:37699|MESH D047428|Gene NX_Q8NFZ5|Gene TNIP2_HUMAN|Gene TNIP2_MOUSE|Species 9606|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Gene NX_Q9UM73|Species 9606|MESH D008223|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Gene NX_Q8NFZ5|Gene TNIP2_HUMAN|Gene TNIP2_MOUSE|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"30804692\",\n",
      "    \"_score\": 22.819511,\n",
      "    \"_source\": {\n",
      "      \"title\": \"Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.\",\n",
      "      \"abstract\": \"The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4-89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5-22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors.\",\n",
      "      \"journal\": \"Lung Cancer (Auckland, N.Z.)\",\n",
      "      \"authors\": \"Barrows SM|Wright K|Copley-Merriman C|Kaye JA|Chioda M|Wiltshire R|Torgersen KM|Masters ET\",\n",
      "      \"affiliations\": \"Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.|Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.|Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA, sbarrows@rti.org.|Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA.|Medical Affairs, Pfizer, Inc., New York, NY, USA.|Medical Affairs, Pfizer Limited, Walton Oaks, UK.|Medical Affairs, Pfizer, Inc., Oslo, Norway.|Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA.\",\n",
      "      \"pubyear\": 2019,\n",
      "      \"entrez_date\": \"2019-02-27\",\n",
      "      \"pmid\": \"30804692\",\n",
      "      \"mesh_terms\": \"\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"\",\n",
      "      \"publication_types\": \"Journal Article|Review\",\n",
      "      \"keywords\": \"ALK|NSCLC|carcinoma|non-small-cell lung|non-small-cell lung cancer\",\n",
      "      \"pmcid\": \"PMC6372008\",\n",
      "      \"doi\": \"10.2147/LCTT.S179349\",\n",
      "      \"medline_ta\": \"Lung Cancer (Auckl)\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|MESH D000078182|Chemical CHEBI:62434|Disease C4878|Disease C7377|MESH D008175|Gene NX_Q9UM73|Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|DisProt_type2 MFUN_04.001|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|MESH D039781|MESH D020504|Gene NX_Q9H4M9|Chemical CHEBI:16044|Chemical CHEBI:49037|Chemical CHEBI:49038|Gene NX_P08581|Gene NX_Q9NWH9|Disease C120945|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|Disease C79777|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Drug L01XE16|Chemical CHEBI:64310|Drug DB08865|MESH D000077547|Disease C14174|Disease C3261|Gene NX_Q9UM73|DisProt_type1 MFUN_04.001|Disease C4878|Disease C7377|MESH D008175|Chemical CHEBI:62434|Gene NX_Q9UM73|Gene NX_Q9UM73|DisProt_type2 MFUN_04.001|DisProt_type2 MFUN_04.001|Chemical CHEBI:62434|Gene NX_Q9UM73|MESH D008175\"\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    \"_index\": \"med20_v2\",\n",
      "    \"_type\": \"citation\",\n",
      "    \"_id\": \"31616196\",\n",
      "    \"_score\": 22.819511,\n",
      "    \"_source\": {\n",
      "      \"title\": \"TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations.\",\n",
      "      \"abstract\": \"Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is an important molecular subgroup of tumors that are typically sensitive to tyrosine kinase inhibitors (TKIs). Although a substantial portion of patients benefit from TKIs, this approach is complicated by intrinsic and acquired resistance. We report a patient with ALK-rearranged NSCLC who showed an initial response to targeted therapy, but developed resistance to multiple TKIs. Serial comprehensive genomic profiling (CGP) was performed at four independent points during the clinical course. We review the pathology and clonal progression of the tumor, with CGP identifying a secondary CTNNB1 p.S45V mutation after the initiation of targeted therapy, followed by tertiary ALK p.I1171N. The presence of an alteration in a second oncogenic driver gene suggests a possible mechanism for resistance, and a secondary therapeutic target. Due to the involvement of Wnt signaling in the pathogenesis of many tumors and its association with immune evasion, a variety of therapeutic strategies are being developed to target this pathway. This case exemplifies the challenges of targeted therapeutics in the face of tumor progression, as well as the increasing role of genomics in understanding tumor biology.\",\n",
      "      \"journal\": \"Lung Cancer (Auckland, N.Z.)\",\n",
      "      \"authors\": \"Ouseph MM|Taber A|Khurshid H|Madison R|Aswad BI|Resnick MB|Yakirevich E|Ali SM|Patel NR\",\n",
      "      \"affiliations\": \"Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA.|Division of Medical Oncology, Miriam Hospital and Alpert Medical School at Brown University, Providence, RI 02906, USA.|Division of Medical Oncology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA.|Foundation Medicine, Inc ., Cambridge, MA 02141, USA.|Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA.|Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA.|Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA.|Foundation Medicine, Inc ., Cambridge, MA 02141, USA.|Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA.\",\n",
      "      \"pubyear\": 2019,\n",
      "      \"entrez_date\": \"2019-10-17\",\n",
      "      \"pmid\": \"31616196\",\n",
      "      \"mesh_terms\": \"\",\n",
      "      \"sup_mesh_terms\": \"\",\n",
      "      \"chemicals\": \"\",\n",
      "      \"publication_types\": \"Journal Article\",\n",
      "      \"keywords\": \"beta-catenin|cancer|genomics|profiling|resistance\",\n",
      "      \"pmcid\": \"PMC6699522\",\n",
      "      \"doi\": \"10.2147/LCTT.S212406\",\n",
      "      \"medline_ta\": \"Lung Cancer (Auckl)\",\n",
      "      \"comments_in\": \"\",\n",
      "      \"comments_on\": \"\",\n",
      "      \"annotations_str\": \"Gene NX_Q9UM73|Gene NX_Q9UM73|Disease C27813|Disease C2852|Disease C3512|Disease C4004|Disease C4025|Disease C4029|MESH D000230|Gene NX_P35222|Gene CTNB1_BOVIN|Gene CTNB1_CANLF|Gene CTNB1_DANRE|Gene CTNB1_HUMAN|Gene CTNB1_MOUSE|Gene CTNB1_RAT|Gene CTNB1_XENLA|Disease C3512|MESH D000077192|Disease C3208|Disease C5165|Disease C7587|MESH D008223|Gene NX_Q9UM73|Disease C2926|Chemical CHEBI:17895|Chemical CHEBI:18186|Drug DB00135|MESH D014443|DisProt_type2 MFUN_04.001|Disease C6916|Disease C4878|Disease C7377|MESH D008175|MESH D011505|MESH D000077548|Gene NX_Q9UM73|Gene ALK_HUMAN|Gene ALK_MOUSE|Chemical CHEBI:38637|Disease C2926|MESH D002289|Gene NX_Q9UM73|Disease C2926|Disease C35461|Gene NX_P35222|Gene CTNB1_BOVIN|Gene CTNB1_CANLF|Gene CTNB1_DANRE|Gene CTNB1_HUMAN|Gene CTNB1_MOUSE|Gene CTNB1_RAT|Gene CTNB1_XENLA|Gene NX_Q9UM73|Disease C18264|Biological Process GO:0009405|Biological Process GO:0042783|MESH D057131|Gene NX_Q9H5J4|Gene NX_Q9HB96|MESH D023281|MESH D001695|Disease C17609|MESH D051176|Gene NX_P35222|Gene CTNB1_BOVIN|Gene CTNB1_CANLF|Gene CTNB1_DANRE|Gene CTNB1_HUMAN|Gene CTNB1_MOUSE|Gene CTNB1_RAT|Gene CTNB1_XENLA|MESH D051176|MESH D023281\"\n",
      "    }\n",
      "  }\n",
      "]\n"
     ]
    }
   ],
   "source": [
    "# call\n",
    "url_API = \"http://candy.hesge.ch/SIBiLS/MEDLINE/search.jsp\"\n",
    "my_json_query = json.dumps(my_query) # json to string\n",
    "my_params = {\"json_query\": my_json_query} # parameters dictionary\n",
    "r = requests.post(url = url_API, params = my_params)\n",
    "\n",
    "# get response and print in output file\n",
    "response = r.text\n",
    "with open(\"SIBiLS_MED_search.json\",\"w\",encoding=\"utf-8\") as file:\n",
    "   file.write(r.text)\n",
    "\n",
    "parsed = json.loads(response)\n",
    "print(json.dumps(parsed['hits'], indent = 2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "32576444 Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.\n",
      "27130468 Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.\n",
      "31147208 Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.\n",
      "24984564 ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer? ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?\n",
      "33277054 GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma. GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.\n",
      "25806324 Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer. Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer.\n",
      "30642554 Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.\n",
      "31521978 The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.\n",
      "30804692 Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.\n",
      "31616196 TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations. TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations.\n"
     ]
    }
   ],
   "source": [
    "for list_item in parsed['hits']:\n",
    "    source_item = list_item['_source']\n",
    "    print(source_item['pmid'],source_item['title'],source_item['title'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "def genOrgan(gene,organ):\n",
    "    \n",
    "    import requests\n",
    "    import json\n",
    "\n",
    "    query = {}\n",
    "\n",
    "    # queries must be formatted in Lucene ElasticSearch style\n",
    "    # https://www.elastic.co/guide/en/elasticsearch/reference/current/full-text-queries.html\n",
    "\n",
    "    # here are different query types :\n",
    "\n",
    "    # MULTI_MATCH queries\n",
    "    # use it for searching in specific fields, with a general OR or AND\n",
    "\n",
    "    search_fields = [\"title\",\"abstract\",\"keywords\",\"mesh_terms\"]\n",
    "    # you can use \"title^3\" for boosting by 3 scores in title\n",
    "    keywords = gene + \" \" + organ\n",
    "    my_operator = \"and\" # default is \"or\"\n",
    "    my_type = \"phrase\" # use it for phrase matching (exact expression)\n",
    "\n",
    "    my_query = {\n",
    "        \"size\": 10, # maximum amount of hits returned\n",
    "        \"from\" : 0, # offset from the first result you want to fetch\n",
    "        \"query\": {\n",
    "            \"multi_match\" : {\n",
    "                \"query\" : keywords,\n",
    "                \"fields\" : search_fields\n",
    "                #,\"operator\" : my_operator\n",
    "                #,\"type\" = \"phrase\"\n",
    "                }\n",
    "            }\n",
    "    }\n",
    "    \n",
    "    # query for required gene and organ\n",
    "    \n",
    "    my_query = {\n",
    "    \"query\": {\n",
    "        \"bool\" : {\n",
    "            \"must\" :[ # AND\n",
    "                {\n",
    "                    \"bool\" : {\n",
    "                        \"should\" :[ # OR\n",
    "                            {\n",
    "                                \"match\" : {\"title\": gene},\n",
    "                                \"match\" : {\"title\": organ}\n",
    "                                }\n",
    "                            ]\n",
    "                        }\n",
    "                    },\n",
    "                {\n",
    "                    \"bool\" : {\n",
    "                        \"should\" :[ # OR\n",
    "                            {\n",
    "                                \"match\" : {\"abstract\": gene},\n",
    "                                \"match\" : {\"abstract\": organ}\n",
    "                                }\n",
    "                            ]\n",
    "                        }\n",
    "                    },\n",
    "                ]\n",
    "            }\n",
    "        }\n",
    "    }\n",
    "    \n",
    "    # call\n",
    "    url_API = \"http://candy.hesge.ch/SIBiLS/MEDLINE/search.jsp\"\n",
    "    my_json_query = json.dumps(my_query) # json to string\n",
    "    my_params = {\"json_query\": my_json_query} # parameters dictionary\n",
    "    r = requests.post(url = url_API, params = my_params)\n",
    "\n",
    "    # get response and print in output file\n",
    "    response = r.text\n",
    "    with open(\"SIBiLS_MED_search.json\",\"w\",encoding=\"utf-8\") as file:\n",
    "       file.write(r.text)\n",
    "\n",
    "    parsed = json.loads(response)\n",
    "    \n",
    "    for list_item in parsed['hits']:\n",
    "        source_item = list_item['_source']\n",
    "        print(source_item['pmid']+'\\n'+source_item['title']+'\\n'+source_item['abstract'])\n",
    "        print('++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "10694605\n",
      "Heart-lung versus double-lung transplantation for suppurative lung disease.\n",
      "OBJECTIVE\n",
      "The purpose of this study was to compare outcomes after heart-lung or double-lung transplantation in patients undergoing transplantation because of end-stage suppurative lung disease.\n",
      "\n",
      "\n",
      "METHODS\n",
      "We reviewed our experience in patients with cystic fibrosis or bronchiectasis who had heart-lung or double-lung transplantation between January 1988 and September 1997. Twenty-three patients (14 male, 21 cystic fibrosis) had heart-lung transplantation and 24 patients (8 male, 19 cystic fibrosis) had double-lung transplantation. There were no statistically significant differences between the groups in age, weight, preoperative creatinine level, cytomegalovirus status, maintenance immunosuppression, or donor demographics. Patients received induction therapy with monoclonal (OKT3) or polyclonal (rabbit anti-thymocyte globulin) antibody.\n",
      "\n",
      "\n",
      "RESULTS\n",
      "Sixteen of 24 patients had double-lung transplantation after 1994 whereas 13 of 22 patients had heart-lung transplantation before 1991, allowing longer follow-up for the heart-lung group. Mean waiting times for transplantation were 270 +/- 245 days (heart-lung) and 361 +/- 229 days (double-lung; P =.20). The 1-, 3-, and 5-year actuarial survival figures were respectively 86%, 82%, and 65% (heart-lung) and 96%, 75%, and unavailable (double-lung; P = no significant difference). The 1-, 3-, and 5-year rates of freedom from obliterative bronchiolitis were respectively 77%, 61%, and 45% (heart-lung) and 86%, 78%, and unavailable (double-lung; P = no significant difference). Linearized overall infection rates (events/100 patient-days) were 2.05 +/- 0.33 (heart-lung) and 2.34 +/- 0.34 (double-lung; P = NS) at 3 months. Thirty-day survival was 100% (heart-lung) and 96% (double-lung). There were 7 late deaths among heart-lung recipients (3 obliterative bronchiolitis, 2 infection, 0 graft coronary artery disease, 2 other) whereas 2 late deaths related to obliterative bronchiolitis occurred in double-lung recipients. Graft coronary artery disease (all stenoses < 50%) affected 15% of heart-lung survivors, whereas 3 double-lung recipients (12.5%) required either bronchial dilatation or stenting.\n",
      "\n",
      "\n",
      "CONCLUSION\n",
      "Heart-lung and double-lung transplantation provide similar palliation for patients with end-stage suppurative lung disease. Therefore double-lung transplantation should be the preferred operation for most patients with end-stage suppurative lung disease.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "11584182\n",
      "Lung transplantation in interstitial lung disease.\n",
      "Interstitial lung disease is a heterogeneous group of illnesses, some of which may progress to a fibrosing stage and cause respiratory failure. For selected candidates, lung transplantation is the ultimate therapeutic option. We review data on lung transplantation for various interstitial lung diseases. We address indications, procedures, and outcomes for patients undergoing transplantation. Unique issues affecting morbidity, mortality, and recurrence of disease are discussed. We review the literature of transplantation for specific interstitial lung diseases and the outcomes of transplantation for interstitial lung diseases. Candidates with idiopathic pulmonary fibrosis experience high mortality on the waiting list, but derive significant survival benefit from lung transplantation. Recurrence is reported for several interstitial lung diseases after lung transplantation. Survival with lung transplantation for interstitial lung diseases is comparable with that attained in recipients with other indications. Lung transplantation is a well-tolerated, effective therapy for respiratory failure in interstitial lung disease.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "23917193\n",
      "[Lung retransplantation; cadaveric lung retransplantation].\n",
      "Lung retransplantation accounts for only 2.6% of all lung transplantations performed worldwide. Overall survival after lung retransplantation is known to be worse than that of initial lung transplantation, but in cautiously selected lung recipients survival has been shown to be equally good. Decision about types of procedure is critical and meticulous patient care is also essential for success.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "28659499\n",
      "Intersections of lung progenitor cells, lung disease and lung cancer.\n",
      "The use of stem cell biology approaches to study adult lung progenitor cells and lung cancer has brought a variety of new techniques to the field of lung biology and has elucidated new pathways that may be therapeutic targets in lung cancer. Recent results have begun to identify the ways in which different cell populations interact to regulate progenitor activity, and this has implications for the interventions that are possible in cancer and in a variety of lung diseases. Today's better understanding of the mechanisms that regulate lung progenitor cell self-renewal and differentiation, including understanding how multiple epigenetic factors affect lung injury repair, holds the promise for future better treatments for lung cancer and for optimising the response to therapy in lung cancer. Working between platforms in sophisticated organoid culture techniques, genetically engineered mouse models of injury and cancer, and human cell lines and specimens, lung progenitor cell studies can begin with basic biology, progress to translational research and finally lead to the beginnings of clinical trials.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "66321\n",
      "Human lung organ-specific antigens on normal lung, lung tumors, and a lung tumor cell line.\n",
      "An antiserum raised in rabbits against a lung tumor cell line (2563) was selected from a library of antisera against normal and malignant human lung, lung tumor cell lines, and fetal tissues and was found by complement fixation, immunofluorescence, and saturation binding assays to contain antibodies for antigens characteristic of those found in normal lung. Studies with the adsorbed antiserum (A49) revealed: 1) An antigen was shared by normal lung and normal kidney (NLK-1) 2) lung tissue-specific antigen(s) were present on normal lung tissue (NL-1); 3) NL-1 was found on both external and internal cell membranes; and 4) NL-1, in addition to being present on normal lung and the adenocarcinoma-derived cell line 2563, was present on 1 of 2 metastatic lung adenocarcinomas but on none of 4 metastatic lung tumors of other histologic types.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "25441143\n",
      "Lung transplantation for multifocal lung adenocarcinoma (multifocal lung carcinoma).\n",
      "Lung transplantation is an acceptable treatment option in highly selected patients with lung limited AIS or MIA. Aside from the cancer diagnosis, ideal candidates should not possess any absolute or relative contraindications to lung transplantation as described by the ISHLT. Confirmation of lung-limited disease and AIS/MIA with lepidic histology and the absence of carcinoma metastatic to mediastinal lymph nodes will optimize outcomes. Those patients with multifocal minimally invasive lung ACA and respiratory insufficiency from severe bronchorrhea may enjoy the best palliation of their disease and have high enough LAS to facilitate transplantation. The role of targeted therapies for those patients with EGFR or ALK-activating mutations and might favorably AIS/MIA has yet to be determined and impact survival and augment (or supplant) lung transplantation for these patients.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "31404527\n",
      "Interstitial Lung Abnormalities and LungCancer Risk in the National LungScreening Trial.\n",
      "BACKGROUND\n",
      "Some interstitial lung diseases are associated with lung cancer. However, it is unclear whether asymptomatic interstitial lung abnormalities convey an independent risk.\n",
      "\n",
      "\n",
      "OBJECTIVES\n",
      "The goal of this study was to assess whether interstitial lung abnormalities are associated with an increased risk of lung cancer.\n",
      "\n",
      "\n",
      "METHODS\n",
      "Data from all participants in the National Lung Cancer Trial were analyzed, except for subjects with preexisting interstitial lung disease or prevalent lung cancers. The primary analysis included those who underwent low-dose CT imaging; those undergoing chest radiography were included in a confirmatory analysis. Participants with evidence of reticular/reticulonodular opacities, honeycombing, fibrosis, or scarring were classified as having interstitial lung abnormalities. Lung cancer incidence and mortality in participants with and without interstitial lung abnormalities were compared by using Poisson and Cox regression, respectively.\n",
      "\n",
      "\n",
      "RESULTS\n",
      "Of the 25,041 participants undergoing low-dose CT imaging included in the primary analysis, 20.2%had interstitial lung abnormalities. Participants with interstitial lung abnormalities had a higher incidence of lung cancer (incidence rate ratio, 1.61; 95%CI, 1.30-1.99). Interstitial lung abnormalities were associated with higher lung cancer incidence on adjusted analyses (incidence rate ratio, 1.33; 95%CI, 1.07-1.65). Lung cancer-specific mortality was also greater in participants with interstitial lung abnormalities. Similar findings were obtained in the analysis of participants undergoing chest radiography.\n",
      "\n",
      "\n",
      "CONCLUSIONS\n",
      "Asymptomatic interstitial lung abnormalities are an independent risk factor for lung cancer that can be incorporated into risk score models.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "2187426\n",
      "Lung and heart-lung transplantation.\n",
      "Unilateral lung transplantation has become a successful method for the treatment of end-stage pulmonary disease, whereas double-lung transplantation has provided benefit to patients with nonfibrotic lung disease such as emphysema and cystic fibrosis. In the past 5 years, 16 single-lung and 13 double-lung transplantations have been performed by the Toronto Lung Transplant Group in patients with end-stage lung disease. Seven perioperative and two late deaths have been recorded so far. Since the introduction of heart-lung transplantation at Stanford in 1981 and at Pittsburgh in 1982 for the treatment of Eisenmenger's syndrome and terminal pulmonary vascular disease, more than 350 combined heart-lung transplantations have been carried out throughout the world. Presently, the 2-year actuarial survival is about 62%. The long-term results have not yet reached the same level of success as those of cardiac transplantation alone. Although several factors have played a role in this difference, a prominent cause has been the lack of a reliable and simple method for pulmonary protection against prolonged ischemia. Most of the techniques proposed against ischemia can be classified as normothermic or static hypothermic cardiopulmonary preservation. The use of the normothermic method has not always been successful. For this reason, interest has now been directed toward the potential for hypothermic preservation of the heart-lung bloc and the use of free-radical scavenger therapy in the reduction of reperfusion injury.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "17285474\n",
      "Quantitative lung perfusion following single lung transplantation.\n",
      "BACKGROUND\n",
      "Following successful lung transplantation, most of the lung perfusion, as well as ventilation, is shifted towards the transplanted lung. We investigated the changes in perfusion during exercise in lung transplant recipients.\n",
      "\n",
      "\n",
      "PATIENTS AND METHODS\n",
      "Twelve patients were included in the study. Six patients had emphysema and 6 patients had idiopathic pulmonary fibrosis (IPF). Patients underwent two upright lung perfusion scans: the first at rest and the second during a maximal cardiopulmonary exercise test. Lung perfusion was assessed in each lung and regionally.\n",
      "\n",
      "\n",
      "RESULTS\n",
      "At rest, patients with emphysema had 83.3 +/- 8 % of total perfusion to the transplanted side and 16.7 +/- 8 % to the native lung, while in the IPF patients, it was 68.7 +/- 12 and 32.7 +/- 10 %, respectively ( P = 0.028). At peak exercise, perfusion shifted from the transplanted lung to the native lung ( P = 0.0095) both in emphysema and IPF patients.\n",
      "\n",
      "\n",
      "CONCLUSIONS\n",
      "Following successful lung transplantation, most of the perfusion is directed towards the transplanted lung. During exercise, there was a small but significant shift towards the native lung. These findings highlighted the important role of the native lung during maximal exercise.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n",
      "19349912\n",
      "Lung cancer and lung transplantation: a review.\n",
      "With the increase in the number of lung transplants, it is expected that there will be a corresponding increase in the number of lung cancers reported in these patients. Longevity of the transplant recipients, lung transplantation for chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, a history of smoking, and the increasing age of the lung donors make lung cancer more likely. Nodules and masses seen in chest imaging in lung transplant patients call for work up until a final diagnosis is achieved because there is a high likelihood of a serious infection or malignancy. The presence of a native lung is a major risk factor for lung cancer occurring in the transplant setting. Lung cancer of donor origin is rare. Bronchioloalveolar carcinoma confined to one lung can potentially be treated by transplanting the affected lung. Treatment for patients with lung cancer in the lung transplant setting has to be individualized because of the complexity of their medical problems and multiple medications. Attention needs to be focused on detecting lung cancer early in these patients to achieve a favorable outcome.\n",
      "++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++\n"
     ]
    }
   ],
   "source": [
    "genOrgan('alk','lung')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
